Trial
NCT02370888
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Florida
Collaborators
Celgene Corporation
Condition
Leukemia, Myeloid
Intervention
Lenalidomide
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-27